Physician profile
Adam Bernstein
NPI 1114915949
$991.58
in general payments reported to CMS, 2019-2025
11 companies · $62.37 in 2025
The $62.37 reported for 2025 was less than what a typical Emergency Medical Services provider received nationally (typical 2025 total: $70.35).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.54 · 2020: $12.42 · 2021: $119 · 2022: $208 · 2023: $325 · 2024: $205 · 2025: $62.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $591.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $541.84 | 2022-2024 | Andexxa, Brilinta |
| Pfizer INC. | $147.09 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $62.31 | 2020-2022 | |
| Chiesi USA, INC. | $59.33 | 2021-2022 | |
| Ucb, INC. | $48.03 | 2023-2024 | Nayzilam, Briviact |
| Argon Medical Devices, INC. | $42.07 | 2021 | |
| Kedrion Biopharma, INC. | $24.96 | 2025 | Rhogam Ultra-Filtered Plus, Albuked, Gammaked |
| Ambu INC. | $17.81 | 2022 | |
| Genentech USA, INC. | $17.29 | 2023 | |
| Gilead Sciences, INC. | $15.89 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $14.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.